As of June 30, 2023, we had cash of approximately $4.6 million and have raised an additional $1.4 million using the Sales Agreement thus far in the third quarter of 2023. With these funds, we expect to be able to fund operations for at least twelve months from the date of the issuance of this Quarterly Report on Form 10-Q.
Item 1.01. Entry into a Material Definitive Agreement.
On July 14, 2023, Virios Therapeutics, Inc. (the “Company”) entered into a Capital On Demand™ Sales Agreement (the “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), pursuant to which the Company may offer and sell, from time to time, through or to the Agent, shares of the Company’s common stock, par value $0.0001 per share, having an aggregate offering price of up to $6.7 million (the “Shares”).
The issuance and sale, if any, of the Shares by the Company under the Agreement will be made pursuant to the Company’s effective registration statement on Form S-3 (Registration Statement No. 333-263700) (as amended, the “Registration Statement”), filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2022, and declared effective on April 28, 2022.